Antiretrovirals
Data on antiretrovirals described by researchers at Kaiser Permanente
Published in AIDS Weekly, May 10th, 2010
According to recent research published in the Jaids - Journal of Acquired Immune Deficiency Syndromes, "Etravirine, a nonnucleoside reverse transcriptase inhibitor, was provided through an international early access program (EAP) prior to regulatory approval. The Phase III, nonrandomized, open-label EAP investigated etravirine 200 mg twice daily plus a background regimen (BR) in patients who had failed multiple antiretroviral regimens."
"Efficacy and safety are reported for HIV-infected adults from the United States through week 48, including subgroups receiving etravirine +/- darunavir/ritonavir and/or raltegravir. The intent-to-treat population included 2578...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2010-05-10)
More Articles from AIDS Weekly
- Virology
Research on virology published by scientists at Center for Disease Control and Prevention - Public Health
Reports outline public health research from INSERM - Mononuclear Leukocytes
Research from University of California in mononuclear leukocytes provides new insights - Pediatrics
Data from University of Stellenbosch provide new insights into pediatrics - HIV/AIDS
Data on HIV/AIDS detailed by researchers at University of Illinois - Experimental Lung Transplantation
Findings from University of Cambridge broaden understanding of experimental lung transplantation - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
